<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37249795</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1559-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>73</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of molecular neuroscience : MN</Title><ISOAbbreviation>J Mol Neurosci</ISOAbbreviation></Journal><ArticleTitle>Differential Expression of MicroRNAs and Predicted Drug Target in Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>375</StartPage><EndPage>390</EndPage><MedlinePgn>375-390</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12031-023-02124-z</ELocationID><Abstract><AbstractText>ALS (Amyotrophic Lateral Sclerosis) is a rare type of neurodegenerative disease. It shows progressive degradation of motor neurons in the brain and spinal cord. At present, there is no treatment available that can completely cure ALS. The available treatments can only increase a patient's life span by a few months. Recently, microRNAs (miRNAs), a sub-class of small non-coding RNAs have been shown to play an essential role in the diagnosis, prognosis, and therapy of ALS. Our study focuses on analyzing differential miRNA profiles and predicting drug targets in ALS using bioinformatics and computational approach. The study identifies eight highly differentially expressed miRNAs in ALS patients, four of which are novel. We identified 42 hub genes for these eight highly expressed miRNAs with Amyloid Precursor Protein (APP) as a candidate gene among them for highly expressed down-regulated miRNA, hsa-miR-455-3p using protein-protein interaction network and Cytoscape analysis. A novel association has been found between hsa-miR-455-3p/APP/serotonergic pathway using KEGG pathway analysis. Also, molecular docking studies have revealed curcumin as a potential drug target that may be used for the treatment of ALS. Thus, the present study has identified four novel miRNA biomarkers: hsa-miR-3613-5p, hsa-miR-24, hsa-miR-3064-5p, and hsa-miR-4455. There is a formation of a novel axis, hsa-miR-455-3p/APP/serotonergic pathway, and curcumin is predicted as a potential drug target for ALS.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Riya Ben</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>#412J, Structural Biology Lab, Pearl Research Park, School of Biosciences &amp; Technology, Vellore Institute of Technology, Vellore-632014, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bajpai</LastName><ForeName>Akhilesh Kumar</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0001-9023-1790</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Genomics, and Informatics, University of Tennessee Health Science Center, Memphis, TN, 38163, USA. akhil.bajpai@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thirumurugan</LastName><ForeName>Kavitha</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-4673-4099</Identifier><AffiliationInfo><Affiliation>#412J, Structural Biology Lab, Pearl Research Park, School of Biosciences &amp; Technology, Vellore Institute of Technology, Vellore-632014, India. m.kavitha@vit.ac.in.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Mol Neurosci</MedlineTA><NlmUniqueID>9002991</NlmUniqueID><ISSNLinking>0895-8696</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>IT942ZTH98</RegistryNumber><NameOfSubstance UI="D003474">Curcumin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C583404">MIRN455 microRNA, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003474" MajorTopicYN="Y">Curcumin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062105" MajorTopicYN="N">Molecular Docking Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="Y">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Drug targets</Keyword><Keyword MajorTopicYN="N">MicroRNAs</Keyword><Keyword MajorTopicYN="N">Microarray data</Keyword><Keyword MajorTopicYN="N">Target genes</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>30</Day><Hour>13</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>30</Day><Hour>11</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37249795</ArticleId><ArticleId IdType="doi">10.1007/s12031-023-02124-z</ArticleId><ArticleId IdType="pii">10.1007/s12031-023-02124-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Edaravone ALS Study Group (2014) Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 15(7&#x2013;8):610&#x2013;617</Citation><ArticleIdList><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Active clinical trial studies (2023) Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. Available at: https://www.cdc.gov/als/ALSResearchNotificationClinicalTrialsStudies_Active.html (Accessed: 7 May 2023)</Citation></Reference><Reference><Citation>Ahmadi M, Agah E, Nafissi S, Jaafari MR, Harirchian MH, Sarraf P, Tafakhori A (2018) Safety and efficacy of nanocurcumin as add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a pilot randomized clinical trial. Neurotherapeutics 15(2):430&#x2013;438</Citation><ArticleIdList><ArticleId IdType="pubmed">29352425</ArticleId><ArticleId IdType="pmc">5935637</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O (2013) The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 9(11):617&#x2013;628</Citation><ArticleIdList><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Sherlock G (2000) Gene ontology: tool for the unification of biology. Nat Genet 25(1):25&#x2013;29</Citation><ArticleIdList><ArticleId IdType="pubmed">10802651</ArticleId><ArticleId IdType="pmc">3037419</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Jones A, Jivraj N, Knights C, Ellis CM, Burman R, Al-Chalabi A (2014) Estimating clinical stage of amyotrophic lateral sclerosis from the ALS Functional Rating Scale. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 15(3&#x2013;4):279&#x2013;284</Citation><ArticleIdList><ArticleId IdType="pubmed">24720420</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Bourne PE (2000) The protein data bank. Nucleic Acids Res 28(1):235&#x2013;242</Citation><ArticleIdList><ArticleId IdType="pubmed">10592235</ArticleId><ArticleId IdType="pmc">102472</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonafede R, Mariotti R (2017) ALS pathogenesis and therapeutic approaches: the role of mesenchymal stem cells and extracellular vesicles. Front Cell Neurosci 11:80</Citation><ArticleIdList><ArticleId IdType="pubmed">28377696</ArticleId><ArticleId IdType="pmc">5359305</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K (2015) Familial amyotrophic lateral sclerosis. Neurol Clin 33(4):807&#x2013;830</Citation><ArticleIdList><ArticleId IdType="pubmed">26515623</ArticleId><ArticleId IdType="pmc">4670044</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown CA, Lally C, Kupelian V, Flanders WD (2021) Estimated prevalence and incidence of amyotrophic lateral sclerosis and SOD1 and C9orf72 genetic variants. Neuroepidemiology 55(5):342&#x2013;353</Citation><ArticleIdList><ArticleId IdType="pubmed">34247168</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruneteau G, Simonet T, Bauch&#xe9; S, Mandjee N, Malfatti E, Girard E, Hanta&#xef; D (2013) Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: potential role in reinnervation ability and disease progression. Brain 136(8):2359&#x2013;2368</Citation><ArticleIdList><ArticleId IdType="pubmed">23824486</ArticleId></ArticleIdList></Reference><Reference><Citation>Bryson JB, Hobbs C, Parsons MJ, Bosch KD, Pandraud A, Walsh FS, Greensmith L (2012) Amyloid precursor protein (APP) contributes to pathology in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Hum Mol Genet 21(17):3871&#x2013;3882</Citation><ArticleIdList><ArticleId IdType="pubmed">22678056</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrera-Juli&#xe1; S, Moreno ML, Barrios C, de la Rubia Ort&#xed; JE, Drehmer E (2020) Antioxidant alternatives in the treatment of amyotrophic lateral sclerosis: a comprehensive review. Front Physiol 11:63</Citation><ArticleIdList><ArticleId IdType="pubmed">32116773</ArticleId><ArticleId IdType="pmc">7016185</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho BS, Irizarry RA (2010) A framework for oligonucleotide microarray preprocessing. Bioinformatics 26(19):2363&#x2013;2367</Citation><ArticleIdList><ArticleId IdType="pubmed">20688976</ArticleId><ArticleId IdType="pmc">2944196</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L, Monteiro MJ (2015) Defective proteasome delivery of polyubiquitinated proteins by ubiquilin-2 proteins containing ALS mutations. PLoS ONE 10(6):e0130162</Citation><ArticleIdList><ArticleId IdType="pubmed">26075709</ArticleId><ArticleId IdType="pmc">4468220</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JJ (2020) Overview of current and emerging therapies for amytrophic lateral sclerosis. Am J Manag Care 26(9 Suppl):S191&#x2013;S197</Citation><ArticleIdList><ArticleId IdType="pubmed">32840332</ArticleId></ArticleIdList></Reference><Reference><Citation>Chico L, Ienco EC, Bisordi C, Lo Gerfo A, Petrozzi L, Petrucci A, Siciliano G (2018) Amyotrophic lateral sclerosis and oxidative stress: a double-blind therapeutic trial after curcumin supplementation. CNS Neurol Disord-Drug Targets (Formerly Curr Drug Targets-CNS Neurol Disord) 17(10):767&#x2013;779</Citation></Reference><Reference><Citation>Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY (2014) cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol 8(4):1&#x2013;7</Citation></Reference><Reference><Citation>Chi&#xf2; A, Hammond ER, Mora G, Bonito V, Filippini G (2015) Development and evaluation of a clinical staging system for amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 86(1):38&#x2013;44</Citation><ArticleIdList><ArticleId IdType="pubmed">24336810</ArticleId></ArticleIdList></Reference><Reference><Citation>Clough E, Barrett T (2016) The gene expression omnibus database. In: Statistical genomics, pp 93-110. Humana Press, New York, NY</Citation></Reference><Reference><Citation>Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7(1):1&#x2013;13</Citation></Reference><Reference><Citation>Dash BP, Naumann M, Sterneckert J, Hermann A (2020) Genome wide analysis points towards subtype-specific diseases in different genetic forms of amyotrophic lateral sclerosis. Int J Mol Sci 21(18):6938</Citation><ArticleIdList><ArticleId IdType="pubmed">32967368</ArticleId><ArticleId IdType="pmc">7555318</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis S, Meltzer PS (2007) GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor. Bioinformatics 23(14):1846&#x2013;1847</Citation><ArticleIdList><ArticleId IdType="pubmed">17496320</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice B, Guida M, Guida M, Coppola C, De Mieri G, Cotrufo R (2012) A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. Gene 508(1):35&#x2013;40</Citation><ArticleIdList><ArticleId IdType="pubmed">22903028</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Pietro L, Lattanzi W, Bernardini C (2018) Skeletal muscle microRNAs as key players in the pathogenesis of amyotrophic lateral sclerosis. Int J Mol Sci 19(5):1534</Citation><ArticleIdList><ArticleId IdType="pubmed">29786645</ArticleId><ArticleId IdType="pmc">5983603</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrawell NE, McAlary L, Lum JS, Chisholm CG, Warraich ST, Blair IP, Yerbury JJ (2020) Ubiquitin homeostasis is disrupted in TDP-43 and FUS cell models of ALS. Iscience 23(11):101700</Citation><ArticleIdList><ArticleId IdType="pubmed">33196025</ArticleId><ArticleId IdType="pmc">7644588</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, M&#xfc;ller K, Ludolph AC, Weishaupt JH (2013) Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol Commun 1(1):1&#x2013;9</Citation></Reference><Reference><Citation>Freischmidt A, M&#xfc;ller K, Zondler L, Weydt P, Volk AE, Bo&#x17e;i&#x10d; AL, Weishaupt JH (2014) Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain 137(11):2938&#x2013;2950</Citation><ArticleIdList><ArticleId IdType="pubmed">25193138</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautier L, Cope L, Bolstad BM, Irizarry RA (2004) affy&#x2014;analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20(3):307&#x2013;315</Citation><ArticleIdList><ArticleId IdType="pubmed">14960456</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Van Den Berg LH (2017) Amyotrophic lateral sclerosis. Nat Rev Dis Primers 3(1):1&#x2013;19</Citation></Reference><Reference><Citation>Huang HY, Lin YCD, Li J, Huang KY, Shrestha S, Hong HC, Huang HD (2020) miRTarBase 2020: updates to the experimentally validated microRNA&#x2013;target interaction database. Nucleic Acids Res 48(D1):D148&#x2013;D154</Citation><ArticleIdList><ArticleId IdType="pubmed">31647101</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen L, J&#xf8;rgensen LH, Bech RD, Frandsen U, Schr&#xf8;der HD (2016) Skeletal muscle remodelling as a function of disease progression in amyotrophic lateral sclerosis. BioMed research international</Citation></Reference><Reference><Citation>Joseph C, Mangani AS, Gupta V, Chitranshi N, Shen T, Dheer Y, Gupta V (2020) Cell cycle deficits in neurodegenerative disorders: Uncovering molecular mechanisms to drive innovative therapeutic development. Aging Dis 11(4):946</Citation><ArticleIdList><ArticleId IdType="pubmed">32765956</ArticleId><ArticleId IdType="pmc">7390532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanehisa M, Goto S (2000) KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28(1):27&#x2013;30</Citation><ArticleIdList><ArticleId IdType="pubmed">10592173</ArticleId><ArticleId IdType="pmc">102409</ArticleId></ArticleIdList></Reference><Reference><Citation>Keon M, Musrie B, Dinger M, Brennan SE, Santos J, Saksena NK (2021) Destination amyotrophic lateral sclerosis. Front Neurol 12:392</Citation></Reference><Reference><Citation>Kiernan MC, Vucic S, Talbot K, McDermott CJ, Hardiman O, Shefner JM, Turner MR (2021) Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol 17(2):104&#x2013;118</Citation><ArticleIdList><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, Bryant SH (2016) PubChem substance and compound databases. Nucleic Acids Res 44(D1):D1202&#x2013;D1213</Citation><ArticleIdList><ArticleId IdType="pubmed">26400175</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Reddy PH (2018) MicroRNA-455-3p as a potential biomarker for Alzheimer&#x2019;s disease: an update. Frontiers in Aging Neuroscience 10:41</Citation><ArticleIdList><ArticleId IdType="pubmed">29527164</ArticleId><ArticleId IdType="pmc">5829054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Reddy AP, Yin X, Reddy PH (2019) Novel MicroRNA-455&#x2013;3p and its protective effects against abnormal APP processing and amyloid beta toxicity in Alzheimer&#x2019;s disease. Biochim Biophys Acta Mol Basis Dis 1865(9):2428&#x2013;2440</Citation><ArticleIdList><ArticleId IdType="pubmed">31181293</ArticleId><ArticleId IdType="pmc">6688505</ArticleId></ArticleIdList></Reference><Reference><Citation>Laneve P, Tollis P, Caffarelli E (2021) RNA deregulation in amyotrophic lateral sclerosis: the noncoding perspective. Int J Mol Sci 22(19):10285</Citation><ArticleIdList><ArticleId IdType="pubmed">34638636</ArticleId><ArticleId IdType="pmc">8508793</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Zhou F, Guan Y, Meng F, Zhao Z, Su Q, Wang X (2022) The Biogenesis of miRNAs and Their Role in the Development of Amyotrophic Lateral Sclerosis. Cells 11(3):572</Citation><ArticleIdList><ArticleId IdType="pubmed">35159383</ArticleId><ArticleId IdType="pmc">8833997</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffler JP, Picchiarelli G, Dupuis L, Gonzalez De Aguilar JL (2016) The role of skeletal muscle in amyotrophic lateral sclerosis. Brain Pathol 26(2):227&#x2013;236</Citation><ArticleIdList><ArticleId IdType="pubmed">26780251</ArticleId><ArticleId IdType="pmc">8029271</ArticleId></ArticleIdList></Reference><Reference><Citation>Majidinia M, Mir SM, Mirza-Aghazadeh-Attari M, Asghari R, Kafil HS, Safa A, Yousefi B (2020) MicroRNAs, DNA damage response and ageing. Biogerontology 21:275&#x2013;291</Citation><ArticleIdList><ArticleId IdType="pubmed">32067137</ArticleId></ArticleIdList></Reference><Reference><Citation>Majidinia M, Karimian A, Alemi F, Yousefi B, Safa A (2020b) Targeting miRNAs by polyphenols: Novel therapeutic strategy for aging. Biochem Pharmacol 173:113688</Citation><ArticleIdList><ArticleId IdType="pubmed">31682793</ArticleId></ArticleIdList></Reference><Reference><Citation>Maor-Nof M, Shipony Z, Lopez-Gonzalez R, Nakayama L, Zhang YJ, Couthouis J, Gitler AD (2021) p53 is a central regulator driving neurodegeneration caused by C9orf72 poly (PR). Cell 184(3):689&#x2013;708</Citation><ArticleIdList><ArticleId IdType="pubmed">33482083</ArticleId><ArticleId IdType="pmc">7886018</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA (2019) ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci 13:1310</Citation><ArticleIdList><ArticleId IdType="pubmed">31866818</ArticleId><ArticleId IdType="pmc">6909825</ArticleId></ArticleIdList></Reference><Reference><Citation>Metsalu T, Vilo J (2015) ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap. Nucleic Acids Res 43(W1):W566&#x2013;W570</Citation><ArticleIdList><ArticleId IdType="pubmed">25969447</ArticleId><ArticleId IdType="pmc">4489295</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, Woolley SC (2009) Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73(15):1218&#x2013;1226</Citation><ArticleIdList><ArticleId IdType="pubmed">19822872</ArticleId><ArticleId IdType="pmc">2764727</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan S, Orrell RW (2016) Pathogenesis of amyotrophic lateral sclerosis. Br Med Bull 119(1):87&#x2013;97</Citation><ArticleIdList><ArticleId IdType="pubmed">27450455</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris GM, Lim-Wilby M (2008) Molecular docking. In: Molecular modeling of proteins (pp 365&#x2013;382). Humana Press</Citation></Reference><Reference><Citation>Muramatsu M, Lapiz MDS, Tanaka E, Grenhoff J (1998) Serotonin inhibits synaptic glutamate currents in rat nucleus accumbens neurons via presynaptic 5-HT1B receptors. Eur J Neurosci 10(7):2371&#x2013;2379</Citation><ArticleIdList><ArticleId IdType="pubmed">9749765</ArticleId></ArticleIdList></Reference><Reference><Citation>Noronha O, Mesarosovo L, Anink JJ, Iyer A, Aronica E, Mills JD (2022) Differentially expressed miRNAs in age-related neurodegenerative diseases: a meta-analysis. Genes 13(6):1034</Citation><ArticleIdList><ArticleId IdType="pubmed">35741796</ArticleId><ArticleId IdType="pmc">9222420</ArticleId></ArticleIdList></Reference><Reference><Citation>Oughtred R, Rust J, Chang C, Breitkreutz BJ, Stark C, Willems A, Tyers M (2021) The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions. Protein Sci 30(1):187&#x2013;200</Citation><ArticleIdList><ArticleId IdType="pubmed">33070389</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmisano R, Golfi P, Heimann P, Shaw C, Troakes C, Schmitt-John T, Bartsch JW (2011) Endosomal accumulation of APP in wobbler motor neurons reflects impaired vesicle trafficking: implications for human motor neuron disease. BMC Neurosci 12(1):1&#x2013;10</Citation></Reference><Reference><Citation>Panio A, Cava C, D&#x2019;Antona S, Bertoli G, Porro D (2022) Diagnostic circulating miRNAs in sporadic amyotrophic lateral sclerosis. Front Med 1207</Citation></Reference><Reference><Citation>Rabinovich-Toidman P, Rabinovich-Nikitin I, Ezra A, Barbiro B, Fogel H, Slutsky I, Solomon B (2015) Mutant SOD1 increases APP expression and phosphorylation in cellular and animal models of ALS. PLoS ONE 10(11):e0143420</Citation><ArticleIdList><ArticleId IdType="pubmed">26600047</ArticleId><ArticleId IdType="pmc">4658003</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman MF, Rahman MR, Islam T, Zaman T, Shuvo MAH, Hossain MT, Moni MA (2019) A bioinformatics approach to decode core genes and molecular pathways shared by breast cancer and endometrial cancer. Informatics in Medicine Unlocked 17:100274</Citation></Reference><Reference><Citation>Raisch J, Darfeuille-Michaud A, Nguyen HTT (2013) Role of microRNAs in the immune system, inflammation and cancer. World J Gastroenterol: WJG 19(20):2985</Citation><ArticleIdList><ArticleId IdType="pubmed">23716978</ArticleId><ArticleId IdType="pmc">3662938</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricci C, Marzocchi C, Battistini S (2018) MicroRNAs as biomarkers in amyotrophic lateral sclerosis. Cells 7(11):219</Citation><ArticleIdList><ArticleId IdType="pubmed">30463376</ArticleId><ArticleId IdType="pmc">6262636</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu DI, Hu Y, Law CW, Shi W, Smyth GK (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):e47</Citation><ArticleIdList><ArticleId IdType="pubmed">25605792</ArticleId><ArticleId IdType="pmc">4402510</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell AP, Wada S, Vergani L, Hock MB, Lamon S, L&#xe9;ger B, Akimoto T (2013) Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis. Neurobiol Dis 49:107&#x2013;117</Citation><ArticleIdList><ArticleId IdType="pubmed">22975021</ArticleId></ArticleIdList></Reference><Reference><Citation>Safa A, Bahroudi Z, Shoorei H, Majidpoor J, Abak A, Taheri M, Ghafouri-Fard S (2020) miR-1: A comprehensive review of its role in normal development and diverse disorders. Biomed Pharmacother 132:110903</Citation><ArticleIdList><ArticleId IdType="pubmed">33096351</ArticleId></ArticleIdList></Reference><Reference><Citation>Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, Lancet D (2010) GeneCards Version 3: the human gene integrator. Database</Citation></Reference><Reference><Citation>Sandyk R (2006) Serotonergic mechanisms in amyotrophic lateral sclerosis. Int J Neurosci 116(7):775&#x2013;826</Citation><ArticleIdList><ArticleId IdType="pubmed">16861147</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Ideker T (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13(11):2498&#x2013;2504</Citation><ArticleIdList><ArticleId IdType="pubmed">14597658</ArticleId><ArticleId IdType="pmc">403769</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanga S, Brambilla L, Tasiaux B, Dang AH, Ivanoiu A, Octave JN, Kienlen-Campard P (2018) A role for GDNF and soluble APP as biomarkers of amyotrophic lateral sclerosis pathophysiology. Front Neurol 9:384</Citation><ArticleIdList><ArticleId IdType="pubmed">29899726</ArticleId><ArticleId IdType="pmc">5988896</ArticleId></ArticleIdList></Reference><Reference><Citation>Su XW, Broach JR, Connor JR, Gerhard GS, Simmons Z (2014) Genetic heterogeneity of amyotrophic lateral sclerosis: implications for clinical practice and research. Muscle Nerve 49(6):786&#x2013;803</Citation><ArticleIdList><ArticleId IdType="pubmed">24488689</ArticleId></ArticleIdList></Reference><Reference><Citation>Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Mering CV (2019) STRING v11: protein&#x2013;protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 47(D1):D607&#x2013;D613</Citation><ArticleIdList><ArticleId IdType="pubmed">30476243</ArticleId></ArticleIdList></Reference><Reference><Citation>Taguchi YH, Wang H (2018) Exploring microRNA biomarker for amyotrophic lateral sclerosis. Int J Mol Sci 19(5):1318</Citation><ArticleIdList><ArticleId IdType="pubmed">29710810</ArticleId><ArticleId IdType="pmc">5983737</ArticleId></ArticleIdList></Reference><Reference><Citation>Talbot K (2014) Amyotrophic lateral sclerosis: cell vulnerability or system vulnerability? J Anat 224(1):45&#x2013;51</Citation><ArticleIdList><ArticleId IdType="pubmed">24010870</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejido C, Pakravan D, Bosch LVD (2021) Potential therapeutic role of HDAC inhibitors in FUS-ALS. Front Mol Neurosci 154</Citation></Reference><Reference><Citation>Trott O, Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455&#x2013;461</Citation><ArticleIdList><ArticleId IdType="pubmed">19499576</ArticleId><ArticleId IdType="pmc">3041641</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeiren Y, Janssens J, Van Dam D, De Deyn PP (2018) Serotonergic dysfunction in amyotrophic lateral sclerosis and Parkinson&#x2019;s disease: similar mechanisms, dissimilar outcomes. Front Neurosci 12:185</Citation><ArticleIdList><ArticleId IdType="pubmed">29615862</ArticleId><ArticleId IdType="pmc">5869258</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt MA, Ehsaei Z, Knuckles P, Higginbottom A, Helmbrecht MS, Kunath T, Taylor V (2018) TDP-43 induces p53-mediated cell death of cortical progenitors and immature neurons. Sci Rep 8(1):1&#x2013;13</Citation></Reference><Reference><Citation>Wakabayashi K, Mori F, Kakita A, Takahashi H, Utsumi J, Sasaki H (2014) Analysis of microRNA from archived formalin-fixed paraffin-embedded specimens of amyotrophic lateral sclerosis. Acta Neuropathol Commun 2(1):1&#x2013;11</Citation></Reference><Reference><Citation>Wang MD, Little J, Gomes J, Cashman NR, Krewski D (2017) Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis. Neurotoxicology 61:101&#x2013;130</Citation><ArticleIdList><ArticleId IdType="pubmed">27377857</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera LC, Nigel Leigh P (2009) Amyotrophic lateral sclerosis. Orphanet J Rare Dis 4(1):1&#x2013;22</Citation></Reference><Reference><Citation>Wu HZY, Thalamuthu A, Cheng L, Fowler C, Masters CL, Sachdev P, Mather KA (2020) Differential blood miRNA expression in brain amyloid imaging-defined Alzheimer&#x2019;s disease and controls. Alzheimer&#x2019;s Res Ther 12(1):1&#x2013;11</Citation></Reference><Reference><Citation>Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Yu G (2021) clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. The Innovation 2(3):100141</Citation><ArticleIdList><ArticleId IdType="pubmed">34557778</ArticleId><ArticleId IdType="pmc">8454663</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S, Chan HS, Hu Z (2017) Using PyMOL as a platform for computational drug design. Wiley Interdiscip Rev Comput Mol Sci 7(2):e1298</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>